{"url_path":"/sec/cphi/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1106644/0001213900-26-057705-index.html","accession_number":"0001213900-26-057705","cik":"0001106644","ticker":"CPHI","issuer_name":"CHINA PHARMA HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1106644/0001213900-26-057705-index.html","primary_entity_key":"0001106644","primary_entity_name":"CHINA PHARMA HOLDINGS, INC."},"word_count":432,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n**(Mark One)** \n\n☒\nQUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.\n\n \n\n**For the quarterly period ended March 31,\n2026**\n\n** **\n\n☐\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.\n\n \n\n**For the transition period from ____________\nto ____________**\n\n \n\n**Commission File Number 001-34471**\n\n \n\n**CHINA\nPHARMA HOLDINGS, INC.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n** **\n\nNevada   75-1564807\n\n(State or other jurisdiction of   (IRS Employer\n\nincorporation or organization)   Identification No.)\n\n     \n\nSecond Floor, No. 17, Jinpan Road\n\nHaikou, Hainan Province, China   570216\n\n(Address of principal executive offices)   (Zip Code)\n\n \n\n+86-898-6681-1730 (China)\n\n(Registrant’s telephone number, including\narea code)\n\n \n\nSecurities registered pursuant\nto Section 12(b) of the Act:\n\n \n\n**Title of each class**   **Trading Symbol(s)**   **Name of each exchange on which registered**\n\nCommon Stock   CPHI   NYSE American\n\n \n\nIndicate by check mark whether\nthe registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the\npreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such\nfiling requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether\nthe registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T\n(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit\nand post such files). Yes ☒ No ☐\n\n  \n\nIndicate by check mark whether\nthe registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging\ngrowth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting\ncompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐   Accelerated filer ☐\n\nNon-accelerated filer ☒     Smaller reporting company ☒\n\n    Emerging growth company ☐\n\n \n\nIf an emerging growth company,\nindicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial\naccounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether\nthe registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n  \n\nAs of May 11, 2026, there\nwere 40,522,002 shares of common stock, $0.001 par value per share, issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n** **\n**Page**\n\n**PART I FINANCIAL INFORMATION**\n1"}